Researchers have developed an AI-based histologic classifier that reads digitized pathology slides from prostate-cancer biopsies or prostatectomy specimens and computes a “risk score” for metastasis and mortality. he AI score  based purely on histopathology  achieved a concordance index (C-index) of 0.81–0.85 for time-to-metastasis prediction in prostatectomy samples, matching or outperforming genomic risk classifiers such as “Decipher” or “Prolaris.” In needle-biopsy based cohorts as well, the AI risk-score had a C-index of ~0.74, which improved further (to ~0.83) when combined with established clinical risk models. 

Independent validation of a version of the tool (PATHOMIQ_PRAD) in a cohort of 344 men who had undergone radical prostatectomy found that high AI-risk scores strongly correlated with both biochemical recurrence and distant metastasis  underscoring real-world prognostic value. 

Advocates believe that such AI-powered pathology tools could transform prostate-cancer care: enabling more accurate risk stratification, helping decide who needs aggressive treatment vs who may be safely monitored, and reducing reliance on costly or less-accessible genomic tests. 

However, experts also urge caution: current AI models remain as adjuncts  not replacements  and more prospective clinical studies and broader validation across diverse populations are needed before widespread adoption.